Get started
Author

Susanne Crocamo

Observed names: S Crocamo, S. Crocamo, Susanne Crocamo Ventilari da Costa
Observed institutions: AC Camargo Hospital, Hospital Moinhos de Vento, Hospital do Câncer III, Hospital de Clínicas de Porto Alegre, Hospital Araújo Jorge, Instituto Nacional de Câncer - INCA, Latin American Cooperative Oncology Group (LACOG), Universidade Federal de Goiás
ORCID: 0000-0002-5463-5517
Observed ORCID: 0000-0002-5463-5517
OpenAlex ID: A5109415876
Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study
2019 · Sergio Daniel Simon, José Bines, et al. · The Breast · 142
FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance
2015 · Gabriela Nestal de Moraes, Deborah Delbue, et al. · Cellular Signalling · 123
Advanced Stage at Diagnosis and Worse Clinicopathologic Features in Young Women with Breast Cancer in Brazil: A Subanalysis of the AMAZONA III Study (GBECAM 0115)
2019 · Maria Alice Franzoi, Daniela D. Rosa, et al. · Journal of Global Oncology · 67
PDF
Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer
2023 · Bruno de Paula, Rosalind Kieran, et al. · Molecular Cancer Therapeutics · 32
Is a Family History of the Breast Cancer Related to Women’s Cancer Prevention Behaviors?
2018 · Neilane Bertoni, Mirian Carvalho de Souza, et al. · International Journal of Behavioral Medicine · 26
Expression of nuclear XIAP associates with cell growth and drug resistance and confers poor prognosis in breast cancer
2020 · Deborah Delbue, Bruna S. Mendonça, et al. · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · 24
Socioeconomic, Clinical, and Molecular Features of Breast Cancer Influence Overall Survival of Latin American Women
2022 · Liz Maria de Almeida, Sandra Cortés, et al. · Frontiers in Oncology · 22
PDF
Real-world assessment of the effect of impact of tumor size on pathological complete response rates in triple negative breast cancer after neoadjuvant chemotherapy
2020 · Bruno Henrique Rala de Paula, Sanjeev Kumar, et al. · Chinese Clinical Oncology · 18
PDF
The Transcriptomic Portrait of Locally Advanced Breast Cancer and Its Prognostic Value in a Multi-Country Cohort of Latin American Patients
2022 · Andrea Sabina Llera, Eliana Saul Furquim Werneck Abdelhay, et al. · Frontiers in Oncology · 14
PDF
Twist1 Influences the Expression of Leading Members of the IL-17 Signaling Pathway in HER2-Positive Breast Cancer Cells
2021 · Bruno R. B. Pires, Renata Binato, et al. · International Journal of Molecular Sciences · 12
PDF
Breast Cancer Quality of Life and Health-state Utility at a Brazilian Reference Public Cancer Center
2019 · Renata Leborato Guerra, Neilane Bertoni Dos Reis, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 12
Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial
2019 · Susanne Crocamo, Renata Binato, et al. · Therapeutic Advances in Medical Oncology · 12
Implementing Standard Diagnosis and Treatment for Locally Advanced Breast Cancer Through Global Research in Latin America: Results From a Multicountry Pragmatic Trial
2024 · Javier Retamales, Adrián Daneri-Navarro, et al. · JCO Global Oncology · 7
PDF
Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer
2022 · Susanne Crocamo, Renata Binato, et al. · International Journal of Molecular Sciences · 7
PDF
Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy
2021 · Laura Testa, Max Mano, et al. · Clinics · 5
PDF
Triple-Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant Chemotherapy
2024 · Bruno de Paula, Susanne Crocamo, et al. · International Journal of Molecular Sciences · 4
PDF
Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER−PR+HER2−) breast cancer
2022 · Bruno Henrique Rala de Paula, Susanne Crocamo, et al. · Translational Breast Cancer Research · 3
PDF
Adjuvant chemotherapy for malignant phyllodes tumor of the breast
2020 · Bruno Henrique Rala de Paula, Renata de Souza Guerra, et al. · World Journal of Advanced Research and Reviews · 3
PDF
Opções Contemporâneas de Rastreio da Cardiotoxicidade Relacionada a Tratamentos Oncológicos
2019 · Bruno de Henrique Rala de Paula, Lívia Liberata Barbosa Bandeira, et al. · Revista Brasileira de Cancerologia · 3
PDF
Advances in Breast Cancer Research: Immunological, Pathological, and Pharmacological Perspectives for Improving Patient Outcomes
2026 · Susanne Crocamo, Everton Cruz dos Santos, et al. · International Journal of Molecular Sciences · 2
PDF
Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In”?
2022 · Bruno Henrique Rala de Paula, Susanne Crocamo · JAMA Oncology · 2
Abstract P1-08-29: Current status of clinical and pathological characteristics of breast cancer patients in Brazil: Results of the AMAZONA III study (GBECAM 0115)
2019 · D Rosa, C Barrios, et al. · Cancer Research · 2
Determinants of delayed postoperative radiation therapy in breast cancer patients undergoing neoadjuvant chemotherapy: A subanalysis of the AMAZONA III prospective cohort
2026 · Júlio César Prestes, Gustavo Viani, et al. · Cancer Treatment and Research Communications · 1
Survival outcomes of Zo-NAnTAx: a five-year analysis of zoledronic acid added to a neoadjuvant regimen for HER2-positive breast cancer
2024 · Bruno de Paula, Eliana Abdelhay, et al. · Annals of Translational Medicine · 1
Is it time to retire sentinel lymph node biopsy and use multi-omics prediction models?
2022 · Rosalind Kieran, Mehmet Goksu, et al. · Annals of Translational Medicine · 1
PDF
Works count: 50
Citation count: 547
H-index: 12
I10-index: 12
Year
Topic
Type